Evidenced by previous research in gastric cancer, pancreatic cancer, and hepatocellular carcinoma, we discern that TRIM50 predominantly performed as a tumor suppressor gene via dampening the output of epithelial–mesenchymal transition (EMT)-related pathway.25–27 However, the role of TRIM50 in breast cancer and its underlying molecular mechanism have not been reported yet and merits further dissection. This evidence concerns the gene TRIM50 and gastric cancer.